A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE

Inclusion Criteria:

• Participants with confirmed unresectable HCC

• Participants with Lung dose threshold for Yttrium 90 glass microspheres of 30 Gy (equal or less than 30 Gy per treatment for glass) and an estimated Future liverremnant volume (FLRV) ≥ 30% of whole liver volume.

• Participants with more than 1 prior embolization are permitted if more than 12months ago, for a different primary lesion, and FLR > 30%.

• Participants with no evidence of extrahepatic disease on any available imaging

• Participants with one or more measurable lesions, unilobar disease for participantswith segmental or right anterior/posterior portal vein invasion (Vp1/Vp2) andeligible for Yttrium 90 glass microspheres TARE.

• Participants having Child-Pugh score class A.

• Participants having ECOG performance status of 0 or 1 at enrollment

• Adequate organ and marrow function

Exclusion Criteria:

• Disease amenable to curative surgery, ablation or transplantation. Transplantpatients are considered eligible if outside of Milan criteria and not currentlylisted for transplant.

• Participants co-infected with HBV and HDV

• Any history of nephrotic or nephritic syndrome.

• Clinically significant (eg, active) cardiovascular disease

• Participants with uncontrolled hypertension

• History of hepatic encephalopathy

• Known hereditary predisposition to bleeding or thrombosis; any prior or currentevidence of bleeding diathesis.

• Receipt of more than 1 prior embolization (TACE or TARE) treatment/procedure

• Participant has received any prior anticancer systemic therapy for unresectable HCC.

• History of arterial thrombotic event, including myocardial infarction, unstableangina, cerebrovascular accident, or transient ischemic attack, within 6 monthsprior to enrollment.

• History of abdominal fistula or gastrointestinal (GI) perforation, non-healedgastric ulcer that is refractory to treatment, or active GI bleeding within 6 monthsprior to enrollment